Basket | Login | Register

 
 
 
 

TRAILBLAZER-ALZ 2 (coming soon)

Phase II trials

Study Information

Name of the study

A Study of Donanemab (LY3002813) in participants with early Alzheimer's disease

Study sponsor

Eli Lilly and Company

Disease

Early Alzheimer's disease

Phase

Phase II

Information about the drug that will be tested in the studies

Name of the drug

Donanemab

Where and when will the study be conducted?

European country involved in the trial (active)

  • Poland

European country that will be involved in the trial (planned)

  • The Netherlands

Information for your doctor

Clinicaltrials.gov identifier

NCT04437511

Link to full text

https://clinicaltrials.gov/ct2/show/NCT04437511

 

 
 

Last Updated: Wednesday 11 November 2020

 

 
 

Options